Cox2 inhibition improves preeclampsia symptoms in a mouse model
Preeclampsia is characterized by elevated blood pressure in the second half of pregnancy and impaired blood flow to the placenta, which increases the risk of premature birth and pregnancy complications. In this issue of JCI Insight, Robin Davisson and colleagues use a mouse model that spontaneously develops cardinal features of preeclampsia to explore its underlying causes. They show that even before preeclampsic symptoms develop, embryos have implantation defects that are associated with increased levels of the pro-inflammatory molecule cyclooxygenase 2 (Cox2). Treatment of mice with the Cox2 inhibitor celecoxib prior to implantation resulted in more typical implantation features, improved fetal growth, and reduced gestational hypertension. These findings support further exploration of Cox2 inhibition early in pregnancy as an approach to prevent preeclampsia.
Decidual Cox2 inhibition improves fetal and maternal outcomes in a preeclampsia-like mouse model
Cornell University College of Veterinary Medicine
View this article at: http://insight.jci.org/articles/view/75351?key=5bcaa55cbc02aacef239
JCI Insight is the newest publication from the American Society of Clinical Investigation, a nonprofit honor organization of physician-scientists. JCI Insight is dedicated to publishing a range of translational biomedical research with an emphasis on rigorous experimental methods and data reporting. All articles published in JCI Insight are freely available at the time of publication. For more information about JCI Insight and all of the latest articles go to http://www.insight.jci.org.